Background: The randomized trial PRODIGE 7 failed to show the benefit of oxaliplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal peritoneal metastasis treatment (CR PM). This systematic review focuses on the association of cisplatin (CDDP) with mitomycin C (MMC) in HIPEC in CR PM. Content: Experimental studies demonstrated that hyperthermia, in addition to CDDP±MMC treatment, gradually improved the cytotoxic effect by increasing early apoptosis, eATP interaction, intracellular CDDP concentration (by 20%) and p73 expression. Recent studies with highly selected patients reported unusual prolonged survival with a median overall survival (OS) of approximately 60 months, with a HIPEC combination of CDDP (25 mg/m 2 /L) plus MMC (3.3 mg/m 2 /L)
Introduction
Colorectal peritoneal metastasis (CR PM), with an occurrence rate of 40% [1, 2] , is the second most common colorectal metastatic disease after hepatic metastases (HM) [3] . Historically, PM was considered a terminal disease. However, the development of combined treatment involving cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) permitted the consideration of peritoneal metastasis (PM) as a metastatic step eligible for locoregional treatment [4] [5] [6] . The fundamental goal of this additional chemotherapeutic treatment is to maximize the total drug concentration in the peritoneal tumor nodules with passive diffusion [7] while minimizing that delivered to the systemic circulation [7] . This treatment permits a median survival of more than 40 months [4, 5, [8] [9] [10] . However, the HIPEC protocol is not standardized. Several chemotherapeutic drugs have been used for CR PM treatment: oxaliplatin [11] , mitomycin C (MMC) [11] or cisplatinium (CDDP). However, there is no consensus on the applied dose, temperature and duration, carrier solution, perfusate volume and technique (open vs. closed) [11] [12] [13] . Oxaliplatin-based HIPEC has been developed by French teams since 2000, whereas MMC is the most commonly used drug worldwide [4, [14] [15] [16] . The survival results seem to be comparable for these two drugs [17] [18] [19] , but oxaliplatin was preferred by many teams because of the duration of the HIPEC protocol (30 min with oxaliplatin vs. 60 or 90 min with MMC), despite the increased risk of postoperative hemorrhage [20] . The number of published randomized trials on CRS and HIPEC is modest thus far, and this treatment will continue to face considerable methodological and practical challenges because of many HIPEC protocols, the choice of an adequate control group (CRS alone or combination chemotherapy?), the surgery in the experimental arm, and the long time period needed for the validity of the results [12, 13] . Recent results of the first phase III trial comparing CRS alone with CRS combined with HIPEC using oxaliplatin failed to demonstrate an overall survival advantage in the HIPEC arm, while the 60-day complication rate was significantly higher [21] . Ceelen proposed some potential explanations for the lack of benefit in the trial: oxaliplatin efficacy issues, adverse effects of intraperitoneal high dose glucose, and potential drawbacks of the use of hyperthermia [10] . Today, the PRODIGE 7 HIPEC protocol (oxaliplatin 30 min 360-460 mg m 2 43°) is abandoned, and the protocol must be redefined: indication, chemotherapy, time of hyperthermia, etc. Recently, the effectiveness of CDDP has been validated in ovarian peritoneal metastasis in a phase III trial offering a HIPEC solution [22] . Is it possible that HIPEC with CDDP has a place in CR PM treatment? In the literature, we note that several teams associate CDDP with MMC in CR PM treatment [23] [24] [25] [26] [27] . Would this association optimize the effectiveness of MMC HIPEC? This systematic review focuses on the association of CDDP in combination with MMC for HIPEC in CR PM.
Materials and methods

Search strategy
This systematic review agrees with the guidelines outlined in the preferred reporting items for systematic reviews and meta-analyses statement (PRISMA). On PubMed, combinations of the following terms were used: "cisplatin," "peritoneal metastasis," "peritoneal carcinomatosis," "colorectal cancer," "experimental," "hyperthermia," "HIPEC" and "colon." We first identified 105 articles with the combination of "peritoneal carcinomatosis" AND "colorectal cancer" AND "cisplatin" and 132 articles with the combination of "experimental" AND "hyperthermia" AND "cisplatin" words. To expand this search, we analyzed 63 articles involving "colorectal cancer" AND "hyperthermia" AND "cisplatin," 50 articles involving "colon" AND "hyperthermia" AND "cisplatin", and 37 articles with the combination of "colon" AND "HIPEC" AND "cisplatin". An initial screening of the title and abstracts was performed.
Eligibility and data extraction
Only studies including a surgical treatment of CR PM with HIPEC including cisplatin with/without MMC were selected. We first deleted duplicate articles and many articles about pressurized intraperitoneal aerosol chemotherapy -cancer (and no HIPEC). We separated experimental and clinical studies. The following studies were excluded: case-control studies, editorials, no fulltext available, and studies in languages other than English. Finally, we analyzed 22 articles: 13 clinical and 9 preclinical studies ( Figure 1) . For clinical studies, we extracted the study design, number of patients, peritoneal cancer index, follow-up, postoperative mortality and morbidity and survival.
"Colorectal cancer" AND "Peritoneal carcinomatosis" AND "Cisplatin" n=105 "experimental" AND "hyperthermia" AND 'cisplatin" n=132 "colorectal cancer" AND "hyperthermia" AND "cisplatin" n=63 "colon" AND "hyperthermia" AND "cisplatin" n=50 "colon" AND "HIPEC" AND "cisplatin" n=37 
Results
Experimental study
In vitro (Table 1) Some experimental studies demonstrated that hyperthermia can affect cell membranes, the cytoskeleton, and the synthesis of macromolecules and can increase drug-induced DNA damage and inhibit the repair of drug-induced DNA damage [28] . CDDP appeared as a drug of choice associated with hyperthermia because hyperthermia provided pharmacokinetic advantages with higher local CDDP concentrations in tissues [29] . First, in gastric cancer cell lines, Tang demonstrated a synergistic effect on inhibiting proliferation and induction of cell death via the apoptotic pathway [30] . In 2018, Cesna validated this synergic effect on colon cancer cells [28] . Caco-2 cells (colon cancer cell line) were treated with CDDP. Hyperthermia gradually improved the cytotoxic effect and decreased the viability of cells by one-fourth from 43°C to 45°C. Furthermore, early apoptosis (20% compared to cells treated in normothermia) and an increase in the intracellular CDDP concentration (by 20%) were induced [28] . Some authors have investigated the role of adenosine triphosphate (ATP) in explaining the synergistic effect of chemotherapy and hyperthermia. ATP is basically undetectable in healthy tissues, whereas in the tumor interstitium, it was found in the hundreds of micromolar range [31] . Hyperthermia (40°C) was noted to improve extracellular ATP-mediated cytotoxicity in MCA38 colon cancer cells [32] . With CDDP or MMC, hyperthermia and extracellular ATP together markedly potentiated cancer cell death [32] . The effects of hyperthermia on CDDP sensitivity were also proposed. Sotille [33] studied the effects of hyperthermia on CDDP sensitivity and determined whether MLH1 and MSH2 are associated with Hsp27 and Hsp72 in MMRdeficient(−)/-proficient(+) cells. We know that the MMR system (mismatch repair system) corrects mismatches and insertion/deletion loops generated during DNA replication, so the HCT116+ch2 (MMR−) and HCT116+ch3 (MMR+) cell lines were exposed to CDDP with or without previous hyperthermia (42°C, 1 h). Whereas hyperthermia increased CDDP resistance in MMR-(1.42-fold), it potentiated CDDP sensitivity in MMR+inducing cell cycle arrest and increasing p73 expression [33] . Sotille first suggested that p73 might participate in the cellular response to hyperthermia and CDDP in an MMR-dependent manner.
In view of these interesting in vitro results, Bhagwandin [34] performed a translational study and proposed to evaluate the utility of in vitro drug sensitivity testing in 27 patients with peritoneal surface malignancies (18.5% from colorectal origin, n=5) undergoing CRS plus HIPEC (chemotherapy agents included MMC or CDDP alone). Seventeen tumors (63%) displayed in vitro sensitivity to the agents used. However, there was no significant difference in survival for patients whose tumors displayed in vitro drug sensitivity vs. those whose tumors did not (p=0.101 and p=0.403, respectively). There was no correlation between in vitro drug sensitivity and the histopathology of the primary neoplasm (p=0.309). Today, it is not recommended to use these assays during the decision-making process in such patients because of the lack of clinical validation.
In vivo (Table 1) The toxicity and effectiveness of the HIPEC procedure with MMC or CDDP were evaluated in preclinical studies.
Makrin showed that this procedure had a detrimental effect on the strength of colonic anastomosis, especially during the early postoperative period (until day 10) [35] . The bursting pressure of anastomoses in rats treated by HIPEC was significantly lower than in controls. On day 7, it was 170, 188, 83 and 19 mmHg in groups 1-4, respectively (p<0.01) (1: surgery only, 2: HIPEC with saline, 3: HIPEC with MMC, and 4: HIPEC with CDDP). This detrimental effect on anastomotic bursting pressure was not observed (p=0.81) in a recent rat model [36] .
The effectiveness of these HIPEC procedures was evaluated in two experimental studies.
Bevanda suggested the synergistic effect of hyperthermia, chemotherapy and immunotherapy and that interleukin-2 (IL-2) significantly increased antitumor activity and the survival rate of mice with CR PM [37] . He compared the cytostatics 5-FU 150 mg/kg, CDDP 10 and MMC 5 mg/kg but did not test the CDDP-MMC association. Combined treatment with IL-2 and cytostatics (5-FU, CDDP or MMMC) significantly affected the development of peritoneal metastasis and increased the survival of mice: ILS% (increased life span) at 37°C=29.88, 199.32 and 108.52, ILS% at 43°C=62.69, 260.50 and 178.05, respectively). The most pronounced effect on survival was achieved by a combination of IL-2, CDDP and hyperthermia at 43°C (ILS% at 37°C=199.32 vs. 260.50 at 43°C; p=0.01852, Kaplan-Meier analysis).
More recently, Yun proposed the development of a novel hydrogel drug delivery system through the combination of 5-fluorouracil (5-FU)-loaded polymeric micelles and CDDP in biodegradable thermosensitive chitosan (CS) hydrogels [38] . The results suggest that intraperitoneal administration of CS hydrogel drug can inhibit tumor Table 1 : Experimental studies about effect of hyperthermia and cisplatin±mitomycin C; main results.
In vitro
Chemotherapeutic protocols
Aim and results 
Cesna
Clinical results
HIPEC protocol (Table 2)
The HIPEC protocol with CDDP and MMC is not standardized. These two chemotherapeutic agents were mainly described by Italian teams. They were the first to publish this HIPEC protocol with oncological results. Cavaliere [23] [24] [25] evaluating the same HIPEC protocol with CDDP+MMC to treat CR PM. He proposed a closed-abdomen HIPEC protocol with the same drug concentrations for 60 min at a temperature of 42.5°C. Pilati [42] published another Italian experience with this HIPEC protocol. Vaira in 2010 [44] proposed a HIPEC protocol according to the original semiclosed abdomen technique, with CDDP 100 mg/m 2 plus MMC 16 mg/m 2 at a temperature of 41.5°C for 60 min. Two Japanese teams described HIPEC with these two chemotherapeutic agents. Yonemura [43] used the same CDDP plus MMC HIPEC protocol as Cavaliere [39, 40] and Baratti [23] [24] [25] . Huang [26] used 120 mg of CDDP and 30 mg of MMC, each dissolved in 6 L of heated saline (drug concentrations: CDDP 20 mg/mL, MMC 5 mg/mL), for 90 min at a temperature of 43.0±0.5°C.
In 2016, Lin [27] published team results in Taiwan with 100 mg of CDDP plus 20 mg of MMC for 60 min at 42-43°C.
Postoperative morbidity (Table 2)
Postoperative mortality after CRS/HIPEC CR PM treatment with CDDP±MMC was described between 0% [42] and 3% [25] , equivalent to the oxaliplatin HIPEC protocol [26] . Major complications occurred is less than 30% (27% in the more recent study) [23] [24] [25] [26] [27] [41] [42] [43] [44] , mostly related to anastomotic leakage, intestinal fistula, abdominal abscess and pleura effusion, with approximately 10% reoperations. Hematological toxicity appeared in less than 15% [25, 42, 44] and hemorrhage between 1% [24] and 2% [26] . These results contrasted with oxaliplatin intraperitoneal toxicity. Hemoperitoneum (22.7%) and grade 3/4 thrombocytopenia (13.3%) were the most frequently reported toxicities with the oxaliplatin HIPEC protocol [45] .
Long-term outcomes and recurrence (Table 2)
The median survival rates described for patients treated with HIPEC were very different, from 16 [26] to 60.1 months [22] . Five-year overall survival also appeared very different, between 22% [26] and 58.8% [25] .
The peritoneal carcinomatosis index (PCI) could explain these survival differences. The majority of patients (53%) treated in Huang's study [26] had an important PM (PCI>20), with a median PCI at 21, whereas Baratti, in a recent study [24] , showed survival of patients with a limited PM (median PCI=10). In a multivariate logistic regression analysis, Baratti confirmed that PCI>19 (OR, 2.6; 95% CI, 1.1-6.0; p=0.02) was an independent predictive factor for major complications [25] .
In addition, Baratti demonstrated that major complications independently affect long-term disease-specific survival (DSS) [25] . Five-year DSS was 14.3% (median, 18.5 months; 95% CI, 15.7-21.1) for patients who experienced major complications and 52.3% (median, 62.8; 95% CI, 23.9-101.7) for those who did not.
Extraperitoneal metastasis appeared as another pejorative survival criterion. In 2018, Baratti [24] compared the long-term outcomes between patients who had CRS/HIPEC for PM alone (n=121, 81.1%) and patients Pinto and Pocard: Colorectal peritoneal metastasis and cisplatin HIPEC undergoing curative-intent treatments for extraperitoneal disease (EPD) (n=27, 18.2 %, 85 % had liver metastasis). The five-year OS was 52.0 % (median=60.1months; 95% CI, 44.9-93.7) for 121 patients treated for PM alone vs. 16.5% (median=19.0 months; 95% CI, 12.1-30.4) for 27 patients treated for EPD, p=0.019.
Prophylactic HIPEC
Two authors, namely, Virzi and Baratti, evaluated the HIPEC protocol with CDDP and MMC at the time of primary curative surgery in patients with colorectal cancer at high risk for metachronous peritoneal metastases [23, 46] .
Virzi published [46] a prospective pilot study with 12 patients to assess the feasibility, safety and efficacy of this same HIPEC protocol combined with primary curative surgery in colorectal cancer at high risk for peritoneal metastases (minimal synchronous peritoneal involvement, synchronous ovarian metastases, primary tumor, either directly invading other organs or penetrating visceral peritoneum, and positive peritoneal washing cytological examination). The protocol was well tolerated and safe. Major morbidity occurred in 17% of cases and operative death in none. The 5-year progression-free and peritoneal progression-free survival rates were 74.1% and 90.9%, respectively. The 5-year overall survival was 83.3%, although one patient died shortly after 5 years.
Baratti [23] published a phase 2 study in 2016 that assessed adjuvant HIPEC in colorectal cancer patients at high risk for metachronous peritoneal metastasis (minimal synchronous peritoneal metastasis, synchronous ovarian metastases, primary tumor either penetrating the visceral peritoneum or directly invading other organs, age<=75 years, WHO performance score<=2, no significant comorbidities, and signed informed consent). He included a number of patients included in the study by Virzi et al., as the latter was a preliminary report of the Italian experience with prophylactic HIPEC. A total of 22 patients without systemic metastases were prospectively enrolled in two centers to receive HIPEC simultaneously with curative surgery. A control group retrospectively included 44 matched (1:2) patients undergoing standard treatments. The Kaplan-Meier estimated 5-year overall survival (OS) was 81.3% in the HIPEC group vs. 70.0% in the control group (p=0.047). No operative death occurred, and severe morbidity rates were 18.2% in the HIPEC group and 25% in controls (p=0.75). In multivariate analysis, HIPEC correlated with a lower cumulative incidence of PM (hazard ratio [HR] 0.04, 95% CI 0.01-0.31; p=0.002), better OS (HR 0.25, 95% CI 0.07-0.89; p=0.039) and progression-free survival (HR 0.31, 95% CI 0.11-0.85; p=0.028). He concluded that adjuvant HIPEC may benefit these patients with a high risk of peritoneal failure.
What is the best treatment after a recurrence?
In some cases, after CR PM treatment by CRS/HIPEC, recurrences may be confined to the peritoneal cavity and are completely resectable. Vaira [47] evaluated the results of 16 patients presenting with isolated peritoneal recurrence who had undergone iterative CRS and HIPEC [47] . Only patients with PCI≤16 and a progression-free interval of at least 12 months between the first HIPEC and the recurrence diagnosis and patients with completely resected disease received a second HIPEC. /L) at a temperature of 41.5-42.5°C for 60-90 min. The survival results described for patients treated with HIPEC combined with CDDP and MMC were very different. We first explain these differences by the peritoneal carcinomatosis index (PCI), which is a very different function of cohorts. However, PCI has been demonstrated by many multivariate analyses to be the most important adverse prognostic factor after CRS-HIPEC [24, 25, 27, 43, 49] . It is important to note that patients treated for PM alone had a very important OS survival (60 months), equivalent or higher than that of patients receiving oxaliplatin IP [10, 19, 50] . Concerning HIPEC morbidity with CDDP, Van Driel [22] did not note an increasing risk of postoperative complications (major morbidity: 25% and 27% for surgery alone vs. the surgery-plus-HIPEC group, p=0.76). In the CR PM literature, major complications occurred in less than 30% (27% in the more recent study). Taken together, all results indicated that the drug concentration, carrier solution, level of hyperthermia or duration is possibly related to the postoperative high complication rate level. For example, 5% dextrose, an oxaliplatin carrier solution, causes metabolic and electrolyte shifts (hyperglycemia and hyponatremia), which may exacerbate surgical morbidity [10] . No clinical studies comparing normothermic with hyperthermic chemoperfusion permit validation of the adverse effects of hyperthermia. However, it is admitted that toxicities within the peritoneal cavity, such as small bowel fistula and anastomotic leakage, undoubtedly increase as the area under the curve for drug dose increases [6] . Regarding the effectiveness and safety, this Italian HIPEC protocol with a combination of CDDP (25 mg/m 2 /L) plus MMC (3.3 mg/m 2 /L) at a temperature of 41.5-42.5°C for 60-90 min could be the rational base to support the design of future randomized trials vs. cytoreductive surgery alone in the treatment of colorectal PM. This protocol represents a potential alternative for now. We expect, in the next 10 years, new drug delivery systems, immunotherapy combined with chemotherapeutic, and development of nanovectorization, a new therapeutic area, to improve actual survival and decrease morbidity [51] . Today, the CDDP+MMC-based HIPEC is the only protocol to demonstrate an adjuvant HIPEC benefit in colorectal cancer patients at high risk for peritoneal failure (5-year overall survival: 81.3% vs. 70% for the HIPEC group vs. the control group, respectively, p=0.047) [23] . During 2006-2012, a total of 22 patients without systemic metastases were prospectively enrolled to receive HIPEC simultaneously with curative surgery. A control group retrospectively included 44 matched (1:2) patients undergoing standard treatments and no HIPEC during the same period. PROPHYLOCHIP, a phase III randomized trial, evaluated surveillance vs. a systematic surgical look with oxaliplatin HIPEC at the end of adjuvant chemotherapy for colorectal cancers operated with a high risk of peritoneal metastasis (perforated tumor, ovarian metastasis, minimal peritoneal disease resected at the same time as the primitive). The results were presented at the 2018 ASCO (American Society of Clinical Oncology) meeting (Goéré, A3531). The Tris trial randomized 150 patients between surveillance and second surgery. Disease-free survival and overall survival at 3 years were not different: 44% vs. 51% and 79% vs. 80%, NS, (second look vs. surveillance, respectively).
The combination of CDDP and MMC might be a valid HIPEC protocol in CR PM. Recent studies evaluating this protocol demonstrated prolonged survival (overall survival approximately 60 months) with limited toxicity. Major complications occurred in less than 30% of cases with few hematological toxicities (less than 15%). This protocol is the only one to demonstrate an adjuvant HIPEC benefit for CRC patients at high risk for peritoneal failure (5-year overall survival 81.3% vs. 70% for the HIPEC group vs. the control group, respectively [p=0.047]). After a recurrence, an iterative procedure is possible with similar recurrence-free disease (13 vs. 13.7 months) and acceptable morbidity (18.7 % severe complications). Randomized trials are now needed to confirm this hypothesis.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared. Employment or leadership: M. Pocard is an expert consultant for GAMIDA company. M. Pocard had commercial relationships with ROCHE, SANOFI, ETHICON company, and Capnomed. Honorarium: None declared. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
